TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03248141

Intervention type: DRUG
Intervention: Hemophilia B standard half-life
Description: Benefix

Intervention type: DRUG
Intervention: Hemophilia B extended half-life
Description: Alprolix

Intervention type: DRUG
Intervention: Hemophilia A standard half-life
Description: Xyntha and other standard half-life agents

Intervention type: DRUG
Intervention: Hemophilia A extended half-life
Description: Eloctate and Adynovate
Study: NCT00805285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Oral Budesonide and Rectal Hydrocortisone
Description: Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
Study: NCT01402063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPX (CT2103)
Description: XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
Study: NCT02209610

Intervention type: DEVICE
Group type: OTHER
Intervention: Electrical and Magnetic Nerve Stimulators
Description: Stimulation of motor nerve and central nervous system

Intervention type: DEVICE
Group type: OTHER
Intervention: Electrical and Magnetic Nerve Stimulators
Description: Stimulation of motor nerve and central nervous system

Intervention type: DRUG
Group type: OTHER
Intervention: Intrathecal Fentanyl
Description: Mu-opioid receptor agonist

Intervention type: DRUG
Group type: OTHER
Intervention: Intrathecal Fentanyl
Description: Mu-opioid receptor agonist
Study: NCT01551810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine
Description: Influenza Virus Vaccine 0.5ml intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine
Description: Influenza Virus Vaccine 0.5ml intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine(contains Preservative)
Description: Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine(contains Preservative)
Description: Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
Study: NCT03014908

Intervention type: OTHER
Intervention: Blood sampling
Description: Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy

Intervention type: OTHER
Intervention: Blood sampling
Description: Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
Study: NCT03993496

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal Aortic Aneurysm Sac Pulsatility
Description: Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~1. Prior to EVAR deployment~2. After EVAR deployment, but before balloon affixation to the aortic wall~3. After EVAR deployment and after affixation
Study: NCT02541942

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment given
Description: For patient convenience, genetic material will be collected in the form of saliva samples.
Study: NCT04658550

Intervention type: OTHER
Intervention: Remote Behaviour Modification Program
Description: The standard of care behaviour modification program for weight loss will be offered virtually due to the COVID-19 pandemic (prospective).

Intervention type: OTHER
Intervention: In Person Behaviour Modification Program
Description: The standard of care behaviour modification program for weight loss was offered in person prior to the COVID-19 pandemic (retrospective).
Study: NCT04058236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: human albumin 5%
Description: Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gelofusine.
Description: Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
Study: NCT00500981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volume challenge

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of internal jugular vein
Study: NCT03106792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hairfinity #1
Description: Main Hairfinity formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hairfinity #2
Description: Variation to main formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hairfinity #3
Description: Variation to main formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredients
Study: NCT00424554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion.
Study: NCT02956083

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Balance eye drops
Description: Propylene Glycol 0.6% Over the counter lipid based artificial tears.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Contacts eye drops
Description: Hydroxypropyl methycellulose over the counter non-lipid based artificial tears

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline - no brand name
Study: NCT02949856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mallinckrodt, COVIDIEN

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube, Unomedica
Study: NCT01004185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol 400 mg
Description: 17-33kg = 3 Asacol 400mg AM \& 2 Asacol 400mg PM; 33-\<54kg = 5 Asacol 400 mg AM \& 4 Asacol 400mg PM; 54-\<90kg = 6 Asacol 400mg AM \& PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol 400 mg
Description: 17-\<33kg = 2 Asacol 400mg \& 1 placebo AM, 1 Asacol 400mg \& 1 placebo PM; 33-\<54kg = 3 Asacol 400mg \& 2 placebo AM, 2 Asacol 400mg \& 2 placebo PM; 54-\<90kg = 3 Asacol 400mg \& 3 placebo AM \& PM
Study: NCT00574483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinacrine
Description: 100 mg day
Study: NCT02788526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant TACE
Description: 1\~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Follow-up
Description: Patients received just follow-up to monitor the recurrence of HCC
Study: NCT04157023

Intervention type: DEVICE
Group type: OTHER
Intervention: Simulator-based Training of Direct Ophthalmoscopy
Description: A digital simulator is used to teach the skills of direct ophthalmoscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: Simulator-based Training of Direct Ophthalmoscopy
Description: A digital simulator is used to teach the skills of direct ophthalmoscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: Simulator-based Training of Direct Ophthalmoscopy
Description: A digital simulator is used to teach the skills of direct ophthalmoscopy
Study: NCT00581464

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Therapy
Description: Standard therapy to help participants with smoking cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Addiction Therapy
Description: A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
Study: NCT03596463

Intervention type: OTHER
Intervention: Breast cancer treatment
Description: Multidisciplinary approach for breast cancer treatment is more beneficial for the patients

Intervention type: OTHER
Intervention: Breast cancer treatment
Description: Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
Study: NCT02292485

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
Study: NCT04067908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling
Description: The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
Study: NCT02751801

Intervention type: OTHER
Intervention: no intervention
Study: NCT01046591

Intervention type: PROCEDURE
Intervention: Polysomnography
Description: Overnight sleep studies will be performed on all children.

Intervention type: PROCEDURE
Intervention: Polysomnography
Description: Overnight sleep studies will be performed on all children.
Study: NCT00594178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motorized bicycle exercise training
Description: Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
Study: NCT03953625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: delivery of the low back pain booklet
Description: When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection.
Study: NCT02513602

Intervention type: PROCEDURE
Intervention: Dental implant insertion
Description: Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
Study: NCT04180306

Intervention type: OTHER
Group type: OTHER
Intervention: pediatric early warning scoring system and resuscitation curriculum
Description: teaching resuscitation to medical providers and implementing a scoring tool to help identify patients at risk for clinical deterioration in an inpatient setting
Study: NCT03798392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-pressurizing Air Q blocker mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion
Description: comparing the airway seal pressure 10 min after insertion of each devices .
Study: NCT04310527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib
Study: NCT00250640

Intervention type: DRUG
Intervention: Iloprost (Ventavis, BAYQ6256)
Description: The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
Study: NCT02176564

Intervention type: DRUG
Intervention: inhaled bronchodilator
Study: NCT00720369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoEnzyme Q10
Description: CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
Study: NCT01196585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-Guided pleural needle biopsy with Abrams' needle
Description: Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography guided cutting pleural needle biopsy
Description: Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
Study: NCT04510610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Decitabine
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
Study: NCT05110014

Intervention type: OTHER
Group type: OTHER
Intervention: Primary Care Office Visits
Description: mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
Study: NCT03738306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mezieres Method
Description: The Mézières treatment have 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain: the paravertebral muscles and latissimus dorsi.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: therapeutic exercise; physical agents
Study: NCT03732781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radspherin
Description: Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days.
Study: NCT00791739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone, pregabalin
Description: * phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~* phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability
Study: NCT03798392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baska mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion
Description: comparing the airway seal pressure 10 min after insertion of each devices .
Study: NCT00444860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live, (Oka-Merck)
Description: A single dose of 0.65 ml of Zostavax injection was given to each study subject
Study: NCT01832454

Intervention type: OTHER
Group type: OTHER
Intervention: Intra thecal inj of autologous MNC
Description: Intra thecal inj of autologous MNC
Study: NCT03807817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Description: Amount of alcohol to be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Description: Amount of alcohol to be administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo Alcohol
Study: NCT02476864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (adult formulation)
Description: Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (adult formulation)
Description: Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (pediatric formulation)
Description: Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (pediatric formulation)
Description: Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
Study: NCT03807817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Alcohol
Description: No Alcohol
Study: NCT00350298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-CDA1/MDX-1388
Description: One Intravenous dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: One Intravenous dose
Study: NCT02571998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan (CLS001) Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Study: NCT03014622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Intramuscular injection
Study: NCT00958412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex®
Description: one (1) 25 mg capsule daily
Study: NCT00182000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: seromycin
Description: 100mg tablet administered 1 hour prior to each therapy session

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavior Therapy
Description: 10 weekly hour-long behavior therapy sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Therapy
Description: 10 weekly hour-long behavior therapy sessions
Study: NCT01810783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
Study: NCT01782560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01813734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: 28 day cycle
Study: NCT01580345

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosa-hexaenoic acid (DHA)
Description: 400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.